PriceTargets.com logo

Cardinal Health - cah Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $127.50
  • Forecasted Upside: 7.80%
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$118.28 As of 12/20/2024 06:31 PM ET
▲ +1.28 (1.09%)

This chart shows the closing price for CAH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cardinal Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CAH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CAH

Analyst Price Target is $127.50
▲ +7.80% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Cardinal Health in the last 3 months. The average price target is $127.50, with a high forecast of $139.00 and a low forecast of $107.00. The average price target represents a 7.80% upside from the last price of $118.28.

This chart shows the closing price for CAH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 13 polled investment analysts is to moderate buy stock in Cardinal Health. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/17/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$127.00 ➝ $136.00
12/13/2024Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$101.00 ➝ $127.00
12/4/2024MizuhoInitiated CoverageHold ➝ Outperform$139.00
11/4/2024Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$119.00 ➝ $124.00
11/4/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$119.00 ➝ $127.00
11/4/2024UBS GroupBoost TargetBuy ➝ Buy$134.00 ➝ $139.00
11/4/2024MizuhoBoost TargetNeutral ➝ Neutral$110.00 ➝ $120.00
11/4/2024BarclaysBoost TargetOverweight ➝ Overweight$117.00 ➝ $133.00
10/22/2024UBS GroupBoost TargetBuy ➝ Buy$125.00 ➝ $134.00
9/11/2024ArgusBoost TargetBuy ➝ Buy$115.00 ➝ $125.00
8/21/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$111.00 ➝ $123.00
8/16/2024Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$115.00 ➝ $119.00
8/15/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$114.00 ➝ $119.00
8/15/2024Wells Fargo & CompanyBoost TargetUnderweight ➝ Underweight$95.00 ➝ $101.00
8/15/2024UBS GroupBoost TargetBuy ➝ Buy$120.00 ➝ $125.00
8/15/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$130.00 ➝ $137.00
8/15/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$105.00 ➝ $115.00
7/19/2024CitigroupLower TargetNeutral ➝ Neutral$115.00 ➝ $107.00
7/9/2024Evercore ISILower TargetIn-Line ➝ In-Line$115.00 ➝ $105.00
7/9/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$129.00 ➝ $130.00
5/15/2024ArgusLower TargetBuy ➝ Buy$120.00 ➝ $115.00
5/3/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$110.00 ➝ $115.00
5/3/2024Robert W. BairdLower TargetOutperform ➝ Outperform$134.00 ➝ $128.00
4/29/2024Wells Fargo & CompanyLower TargetUnderweight ➝ Underweight$96.00 ➝ $94.00
2/26/2024Leerink PartnrsReiterated RatingOutperform
2/26/2024Leerink PartnersInitiated CoverageOutperform$125.00
2/9/2024ArgusUpgradeHold ➝ Buy
2/5/2024UBS GroupBoost TargetBuy ➝ Buy$122.00 ➝ $125.00
1/29/2024UBS GroupBoost TargetBuy ➝ Buy$114.00 ➝ $122.00
1/3/2024BarclaysInitiated CoverageOverweight$117.00
12/14/2023Wells Fargo & CompanyInitiated CoverageUnderweight$96.00
11/17/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$101.00 ➝ $112.00
10/11/2023Evercore ISILower Target$100.00 ➝ $95.00
8/16/2023TD CowenBoost TargetMarket Perform ➝ Market Perform$88.00 ➝ $90.00
8/16/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$92.00 ➝ $100.00
8/16/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$93.00 ➝ $101.00
8/16/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$107.00 ➝ $108.00
8/16/2023MizuhoBoost TargetNeutral ➝ Neutral$94.00 ➝ $96.00
7/17/2023Bank of AmericaBoost Target$91.00 ➝ $99.00
7/11/2023MizuhoBoost Target$85.00 ➝ $94.00
6/12/2023Credit Suisse GroupBoost Target$90.00 ➝ $100.00
6/12/2023CitigroupBoost Target$88.00 ➝ $90.00
6/11/2023UBS GroupBoost Target$93.00 ➝ $97.00
6/9/2023Evercore ISIBoost Target$90.00 ➝ $95.00
6/9/2023JPMorgan Chase & Co.Boost Target$90.00 ➝ $93.00
6/9/2023Bank of AmericaBoost Target$85.00 ➝ $91.00
6/9/2023Robert W. BairdBoost Target$97.00 ➝ $103.00
6/9/2023MizuhoBoost Target$76.00 ➝ $85.00
6/9/2023BarclaysBoost Target$80.00 ➝ $85.00
5/8/2023Deutsche Bank AktiengesellschaftBoost Target$88.00 ➝ $90.00
5/5/2023UBS GroupBoost Target$91.00 ➝ $93.00
5/5/2023BarclaysBoost Target$77.00 ➝ $80.00
4/26/2023Deutsche Bank AktiengesellschaftBoost Target$77.00 ➝ $88.00
3/31/2023CitigroupInitiated CoverageNeutral$77.00
3/22/2023Deutsche Bank AktiengesellschaftLower TargetHold$82.00 ➝ $77.00
2/3/2023Morgan StanleyBoost TargetOverweight$86.00 ➝ $90.00
2/3/2023Credit Suisse GroupBoost TargetNeutral$89.00 ➝ $92.00
2/3/2023Robert W. BairdUpgradeNeutral ➝ Outperform$87.00 ➝ $94.00
1/31/2023UBS GroupBoost TargetBuy$78.00 ➝ $91.00
1/6/2023Morgan StanleyBoost TargetOverweight$82.00 ➝ $86.00
11/22/2022Credit Suisse GroupBoost TargetNeutral$64.00 ➝ $79.00
11/14/2022MizuhoBoost TargetNeutral$66.00 ➝ $74.00
11/7/2022Morgan StanleyBoost TargetOverweight$76.00 ➝ $82.00
11/7/2022Robert W. BairdBoost TargetNeutral$74.00 ➝ $82.00
11/4/2022Bank Of America (Bofa)UpgradeUnderperform ➝ Neutral$64.00 ➝ $80.00
11/4/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$64.00 ➝ $80.00
10/13/2022Robert W. BairdBoost Target$74.00
8/29/2022UBS GroupBoost TargetBuy$61.00 ➝ $78.00
8/22/2022Morgan StanleyBoost TargetOverweight$70.00 ➝ $76.00
8/16/2022CowenBoost TargetMarket Perform$59.00 ➝ $72.00
8/16/2022CowenBoost TargetMarket Perform$59.00 ➝ $72.00
8/15/2022Evercore ISIBoost Target$75.00
8/15/2022BarclaysBoost Target$67.00
8/12/2022MizuhoBoost Target$58.00 ➝ $66.00
8/12/2022Credit Suisse GroupBoost TargetNeutral$56.00 ➝ $64.00
8/12/2022Robert W. BairdBoost TargetNeutral$57.00 ➝ $73.00
7/14/2022Morgan StanleyLower TargetOverweight$74.00 ➝ $70.00
5/26/2022BarclaysDowngradeOverweight ➝ Equal Weight$70.00 ➝ $64.00
5/18/2022Evercore ISIUpgradeIn-Line ➝ Outperform$55.00 ➝ $68.00
4/12/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$74.00
2/4/2022Credit Suisse GroupLower TargetNeutral$60.00 ➝ $58.00
2/4/2022Robert W. BairdBoost Target$52.00 ➝ $57.00
1/11/2022BarclaysLower TargetOverweight$65.00 ➝ $63.00
12/17/2021Morgan StanleyLower TargetEqual Weight$64.00 ➝ $54.00
11/15/2021Credit Suisse GroupLower TargetNeutral$53.00 ➝ $50.00
11/12/2021Deutsche Bank AktiengesellschaftBoost TargetHold$51.00 ➝ $59.00
11/10/2021MizuhoLower TargetNeutral$56.00 ➝ $53.00
11/10/2021BarclaysLower TargetOverweight$68.00 ➝ $65.00
8/6/2021Evercore ISIReiterated RatingHold$50.00
8/6/2021BarclaysLower TargetOverweight$71.00 ➝ $68.00
8/6/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$62.00 ➝ $51.00
8/5/2021CitigroupDowngradeBuy ➝ Underperform$69.00 ➝ $56.00
8/5/2021Bank of AmericaDowngradeBuy ➝ Underperform$69.00 ➝ $56.00
7/13/2021Deutsche Bank AktiengesellschaftSet TargetBuy$57.44
5/17/2021Robert W. BairdReiterated RatingOutperform ➝ Neutral$66.00 ➝ $64.00
5/10/2021Robert W. BairdDowngradeOutperform ➝ Neutral$66.00 ➝ $64.00
3/3/2021Morgan StanleyLower TargetEqual Weight$66.00 ➝ $64.00
1/8/2021Wolfe ResearchUpgradeUnderperform ➝ Peer Perform
11/13/2020MizuhoBoost TargetNeutral$56.00 ➝ $59.00
11/9/2020Morgan StanleyBoost TargetEqual Weight$61.00 ➝ $66.00
11/6/2020Robert W. BairdBoost TargetOutperform$64.00 ➝ $70.00
11/6/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$61.00 ➝ $65.00
11/2/2020BarclaysUpgradeEqual Weight ➝ Overweight$57.00
9/25/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$66.00 ➝ $61.00
8/10/2020UBS GroupLower TargetBuy$65.00 ➝ $64.00
8/7/2020Morgan StanleyBoost TargetEqual Weight$59.00 ➝ $61.00
7/21/2020Bank of AmericaBoost TargetBuy$61.00 ➝ $63.00
7/20/2020GuggenheimUpgradeNeutral ➝ Buy
6/15/2020Morgan StanleyBoost TargetEqual Weight$57.00 ➝ $59.00
5/15/2020Bank of AmericaUpgradeBuy
5/15/2020UBS GroupUpgradeNeutral ➝ Buy$48.00 ➝ $64.00
5/12/2020MizuhoBoost TargetNeutral$50.00 ➝ $56.00
5/12/2020Morgan StanleyBoost TargetEqual Weight$51.00 ➝ $57.00
5/11/2020CfraLower TargetHold$61.00 ➝ $58.00
4/22/2020Credit Suisse GroupDowngradeHold$53.00
3/27/2020Morgan StanleyLower TargetEqual Weight$64.00 ➝ $51.00
3/20/2020Bank of AmericaUpgradeUnderperform ➝ Buy$57.00 ➝ $58.00
2/12/2020Morgan StanleyUpgradeUnderweight ➝ Equal Weight$48.00 ➝ $64.00
2/7/2020MizuhoBoost TargetNeutral$52.00 ➝ $58.00
2/7/2020Robert W. BairdUpgradeNeutral ➝ Outperform$54.00 ➝ $68.00
2/6/2020CfraBoost TargetHold$56.00 ➝ $61.00
1/19/2020BarclaysReiterated RatingHold$54.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.39 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 31 very positive mentions
  • 15 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
Mentions as of
5/25/2024
  • 26 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 29 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 36 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 37 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 26 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 47 very positive mentions
  • 29 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 69 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 69 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Cardinal Health logo
Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Read More

Today's Range

Now: $118.28
Low: $116.03
High: $118.86

50 Day Range

MA: $117.49
Low: $107.89
High: $125.33

52 Week Range

Now: $118.28
Low: $93.17
High: $126.23

Volume

9,160,340 shs

Average Volume

2,130,367 shs

Market Capitalization

$28.62 billion

P/E Ratio

23.01

Dividend Yield

1.75%

Beta

0.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Cardinal Health?

The following Wall Street sell-side analysts have issued research reports on Cardinal Health in the last twelve months: Argus, Barclays PLC, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Mizuho, Morgan Stanley, Robert W. Baird, StockNews.com, TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for CAH.

What is the current price target for Cardinal Health?

0 Wall Street analysts have set twelve-month price targets for Cardinal Health in the last year. Their average twelve-month price target is $127.50, suggesting a possible upside of 7.8%. UBS Group AG has the highest price target set, predicting CAH will reach $139.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $107.00 for Cardinal Health in the next year.
View the latest price targets for CAH.

What is the current consensus analyst rating for Cardinal Health?

Cardinal Health currently has 5 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CAH.

What other companies compete with Cardinal Health?

Other companies that are similar to Cardinal Health include McKesson, Cencora, Henry Schein, Patterson Companies and Owens & Minor. Learn More about companies similar to Cardinal Health.

How do I contact Cardinal Health's investor relations team?

Cardinal Health's physical mailing address is 7000 CARDINAL PLACE, DUBLIN OH, 43017. The company's listed phone number is (614) 757-5000 and its investor relations email address is [email protected]. The official website for Cardinal Health is www.cardinalhealth.com. Learn More about contacing Cardinal Health investor relations.